Ainos Inc

Ainos, Inc. is a healthcare company engaged in the discovery and development of pharmaceutical and biotech products. It operates through the following divisions: Pharmaceutical, Medical, and Consumer. The company was founded in June 1984 and is headquartered in San Diego, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. Its medtech solutions include COVID-19 Antigen Rapid Test Kit, VOC POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha, and Synthetic RNA. The company was founded on June 26, 1984 and is headquartered in San Diego, CA.

Five VELDONA® Pet products are now available New supplements will launch in Taiwan in July ahead of the planned international release, helping to maintain immunity for millions of pets Ainos sets its sights on entering the $137 billion US pet market SAN DIEGO, CA / ACCESSWIRE / June 14, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the launch of two new VELDONA® Pet cytoprotein supplement products. VELDONA® Pet Shiny, formulated to support pets' eye health, and VELDONA® Pet Slim, designed to help manage body weight and weight-related health issues, will be launched next month in Taiwan.

Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target

New products support pets' emotional health and allergic responses, hit market in Taiwan following successful launch of VELDONA® Pet Expanding VELDONA® Pet product line builds growth momentum toward US$20M sales target for 2024 SAN DIEGO, CA / ACCESSWIRE / June 7, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the launch of two new additions to its VELDONA® Pet cytoprotein supplement product line. VELDONA® Pet Lohas, designed to support pets' emotional health and relieve stress, and VELDONA® Pet Soothing, formulated to relieve discomfort caused by allergies, will be launched in Taiwan in July.

Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target

VELDONA® Pet will hit shelves in Taiwan in June, with launches in other regions to follow Multiple new VELDONA® Pet products set to launch as Ainos enters the growing global pet care market SAN DIEGO, CA / ACCESSWIRE / May 30, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has launched its VELDONA® Pet cytoprotein health supplements. VELDONA® Pet will first be marketed in Taiwan in June, with near-term plans to expand sales and marketing in other markets.

Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales

Current CFO Celia Wu announces her retirement and transition to consulting role Sung brings nearly two decades of public company audit and compliance experience with major international accounting firms SAN DIEGO, CA / ACCESSWIRE / May 17, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the appointment of Ms. Meng-Lin (Amanda) Sung to the position of Chief Financial Officer, effective May 17, 2023.

Ainos Appoints Amanda Sung as New Chief Financial Officer

Ainos continues its strategic transition away from marketing COVID test kits and further advances commercialization of its VELDONA® and VOC POCT technologies Strategic pivot is underpinned by Ainos' diversified product pipeline SAN DIEGO, CA / ACCESSWIRE / May 12, 2023 / Ainos, Inc.Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2023. Chun-Hsien Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "The first quarter of 2023 marks the beginning of a new chapter for Ainos.

Ainos Reports First Quarter 2023 Financial Results

Revenues increased by 3,832% year over year Debt ratio improved to 7% from 75% at year-end 2021 SAN DIEGO, CA / ACCESSWIRE / March 31, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights Revenues were US$1,038,025 in the fourth quarter of 2022, up 3,832% year over year.

Ainos Reports Fourth Quarter and Full Year 2022 Financial Results

Ainos expands market for VELDONA® low-dose interferon treatment to animal care Products expected to launch in Taiwan in Q3 2023 SAN DIEGO, CA / ACCESSWIRE / March 21, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has signed a distribution agreement (the "Agreement") with Topmed International Biotech Co., Ltd. ("Topmed"), a Taiwanese biotech company.

Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan

Meta Materials

RLX Technology

Use these tips for buying penny stocks after hours The post Tips for Buying Penny Stocks During After Hours appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Tips for Buying Penny Stocks During After Hours

Ainos advances commercialization of its VELDONA® low-dose interferon treatment through strategic partnerships SAN DIEGO, CA / ACCESSWIRE / March 14, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has signed a Memorandum of Understanding ("MoU") with Merdury Biopharmaceutical Corp., a Taipei Exchange Emerging Stock Board listed company (TPEx: Code 6932) ("Merdury"), to jointly explore and develop a strategic business relationship. The MoU is an important component of Ainos' strategy to advance commercialization of its VELDONA® formulation.

Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients

SAN DIEGO, CA / ACCESSWIRE / March 13, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has entered into two convertible note purchase agreements, under which the Company has issued and sold two convertible promissory notes (the "Notes") in a principal amount of US$3 million to certain investors. The Notes will mature in two years following the issuance, bearing interest at the rate of 6% per annum.

Ainos Announces US$3 Million Convertible Notes Private Placement

Ainos advances commercialization of its VELDONA® low-dose interferon treatment through strategic partnerships Ainos intends to begin clinical trials into VELDONA®'s potential veterinary applications in the first quarter of 2023 SAN DIEGO, CA / ACCESSWIRE / January 23, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it has signed a Memorandum of Understanding ("MoU") with Taiwanese animal drug manufacturer Tah-An Chemical & Pharmaceutical Co., Ltd. ("Tah-An").

Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug

SAN DIEGO, CA / ACCESSWIRE / January 17, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, is pleased to provide the following shareholder letter from Ainos' Chairman of the Board, President, and Chief Executive Officer, Mr. Chun-Hsien Tsai.

Ainos Issues 2023 Shareholder Letter

Revenues increased by 384% year over year Debt ratio decreased to 7% from 75% at year-end 2021 SAN DIEGO , Nov. 7, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Highlights Revenues were US$1,757,774 in the third quarter of 2022, up 384.2% year over year.

Ainos Reports Unaudited Third Quarter 2022 Financial Results

The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization SAN DIEGO , Nov. 3, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha ("IFNα") formulation, VELDONA®. Ainos has completed Phase 2 trials for the five new drug candidates and will work with potential partners to accelerate the candidates to Phase 3 trials and eventual commercialization of VELDONA®.

Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation

Clinical results thus far have shown low-dose oral interferon's promising efficacy as a new treatment or as an alternative to high-dose injectable interferon SAN DIEGO, CA / ACCESSWIRE / October 31, 2022 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha ("IFNα") formulation, VELDONA®. Ainos has completed Phase 2 trials for the five new drug candidates and will work with potential partners to accelerate the candidates to Phase 3 trials and eventual commercialization of VELDONA®.

Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization

Alset EHome International

SciSparc Ltd

Which penny stocks are you watching right now? The post Buying Penny Stocks This Week?

Buying Penny Stocks This Week? What You Need to Know

FingerMotion

F45 Training Holdings

Which penny stocks are on your buy list this week? The post New to Trading Penny Stocks?

New to Trading Penny Stocks? Beginner Must Knows

Source: Shutterstock Ainos (NASDAQ: AIMD ) stock is gaining on Friday after seeing positive results from hamster trials of its Covid-19 treatment. These trials saw the company measuring the effectiveness of VELDONA over a 16-day period.

Why Is Ainos (AIMD) Stock Skyrocketing Today?

VELDONA® formulation showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period. By upregulation of immunomodulatory, Ainos' VELDONA® formulation demonstrates efficacy against new variant virus based on clinical symptoms and lung inflammation.

Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron

SAN DIEGO, CA / ACCESSWIRE / August 24, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA®, for treatment of mild symptoms related to COVID-19. If approved, the Company's Phase 2 trial is expected to involve a multicenter, parallel, randomized study conducted in Taiwan to evaluate the efficacy of VELDONA® in subjects with mild symptoms related to COVID-19.

Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms

SAN DIEGO, CA / ACCESSWIRE / August 17, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced it has signed a Master Service Agreement with Swiss Pharmaceutical Co., Ltd. (Taiwan) ("Swiss Pharma").

Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates

SAN DIEGO, CA / ACCESSWIRE / August 15, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial Highlights Revenues were US$636,627 in the second quarter of 2022, up 213.6% from US$202,992 in the same period of 2021.

Ainos Reports Second Quarter 2022 Financial Results

SAN DIEGO, CA / ACCESSWIRE / August 11, 2022 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the closing of its previously announced underwritten public offering of 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consisted of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25.

Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split

SAN DIEGO, CA / ACCESSWIRE / August 8, 2022 / Ainos, Inc. (OTC PINK:AIMD) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the pricing of its underwritten public offering of 780,000 units at a public offering price of $4.25 per unit. Each unit issued in the offering consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $4.25.

Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split

Hamsters Receiving Ainos' VELDONA Formulation Demonstrate Protection from COVID-19 Based on Prespecified Indicators of Clinical Outcomes SAN DIEGO , June 27, 2022  /PRNewswire/ -- Ainos, Inc. (OTC PINK: AIMD) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the topline results from its COVID-19 antiviral efficacy study in hamsters (the "Study"). The available results show that its low-dose oral interferon alpha ("IFN-α") formulation, VELDONA, has a protective effect on lungs infected with the SARS-CoV-2 (the "Delta variant") virus by regulating the immune response, thus expediting recovery of infected animals.

News for Ainos Inc Stock (AIMD)